H-plk activators pertain to a class of chemical compounds that are designed to modulate the activity of a specific family of enzymes known as Polo-like kinases (Plks). These kinases are a group of serine/threonine-protein kinases which play a pivotal role in cell cycle progression, mitotic entry, and the maintenance of genomic stability. The "H" in H-plk activators often denotes a specific attribute or structural feature of these molecules that enables them to interact with the Plk enzymes, potentially leading to an increase in the kinase's activity. These activators are typically characterized by their ability to bind to the regulatory domains of Plks, which can include the polo-box domain (PBD) that is critical for substrate recognition and the proper localization of the kinase within the cell.
The structural design of H-plk activators is a sophisticated endeavor that involves a profound understanding of the molecular intricacies of the Plk enzymes. The architecture of these activators is often tailored to fit into the active site or to interact with specific allosteric sites on the kinase. This interaction can induce a conformational change that either directly stimulates the kinase's catalytic activity or stabilizes the enzyme in an active form. These chemical interactions are underpinned by a complex interplay of hydrogen bonds, hydrophobic interactions, and van der Waals forces, which together ensure the specificity and efficacy of the activator. The specificity is crucial, as Plks are part of a larger family of kinases, and off-target effects could lead to unintended consequences within the cellular environment. Therefore, the molecular design of H-plk activators often incorporates a level of precision that allows for the distinction between closely related kinases, thereby offering a degree of selectivity that is essential for their functional engagement with the target Polo-like kinases.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
BI 2536 | 755038-02-9 | sc-364431 sc-364431A | 5 mg 50 mg | $151.00 $525.00 | 8 | |
BI 2536 is a potent Plk1 inhibitor that leads to spindle defects and mitotic arrest, which paradoxically can activate H-plk through compensatory mechanisms in the cell cycle checkpoint, leading to an attempt to correct spindle defects and push through mitosis. | ||||||
GSK461364 | 929095-18-1 | sc-364504 sc-364504A | 10 mg 50 mg | $500.00 $1540.00 | ||
GSK461364 is a selective Plk1 inhibitor which can lead to mitotic block, indirectly causing an increase in H-plk activity as the cell attempts to complete mitosis despite the block. | ||||||
BI6727 | 755038-65-4 | sc-364432 sc-364432A sc-364432B sc-364432C sc-364432D | 5 mg 50 mg 100 mg 500 mg 1 g | $150.00 $1050.00 $1665.00 $3329.00 $4382.00 | 1 | |
Volasertib is a potent and selective Plk1 inhibitor which causes mitotic arrest, leading to indirect activation of H-plk as the cell cycle checkpoint machinery attempts to resolve the arrest and progress through the cell cycle. | ||||||
Thymoquinone | 490-91-5 | sc-215986 sc-215986A | 1 g 5 g | $47.00 $133.00 | 21 | |
Thymoquinone, though not a direct inhibitor of Plk1, can interfere with microtubule dynamics and potentially induce a stress response within the cell that activates H-plk as a part of the cellular adaptation to mitotic stress. | ||||||